Angiogenesis in the infarcted myocardium

Antioxidants and Redox Signaling

Volumn 18, Issue 9, 2013, Pages 1100-1113

  Cochain, Clement ^a   Channon, Keith M ^b   Silvestre, Jean Sébastien ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MICRORNA; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE HEART INFARCTION; ANGIOGENESIS; ENDOTHELIAL PROGENITOR CELL; GENE TRANSFER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LIMB ISCHEMIA; NONHUMAN; PHAGOCYTOSIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW;

ADULT STEM CELLS; ANGIOGENESIS INDUCING AGENTS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAPILLARIES; CELL COMMUNICATION; CLINICAL TRIALS AS TOPIC; CORONARY CIRCULATION; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; GENETIC THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INDUCED PLURIPOTENT STEM CELLS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICROCIRCULATION; MICRORNAS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE; REPERFUSION INJURY; STEM CELL TRANSPLANTATION;

EID: 84874069796     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4849     Document Type: Review

References (126)

1. Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fandrich F, Siebert R, Cooke JP, Dimmeler S, and Heeschen C. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 100: 581-589, 2007.
2. Alitalo K and Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219-227, 2002.
3. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, and Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101: 40-50, 1998.
4. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM. Isolation of putative progenitor endothelial cells for an-giogenesis. Science 275: 964-967, 1997.
5. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, and Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106: 3009-3017, 2002.
6. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Shibuya M, Collen D, Conway EM, and Carmeliet P. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943, 2003.
7. Banai S, Jaklitsch MT, Casscells W, Shou M, Shrivastav S, Correa R, Epstein SE, and Unger EF. Effects of acidic fi-broblast growth factor on normal and ischemic myocardium. Circ Res 69: 76-85, 1991.
8. Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, and Willette RN. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 56: 147-155, 2010.
9. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E, Varda-Bloom N, Nass D, Engelberg S, Eldar M, and et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 22: 2001-2006, 1993.
10. Bekkers SC, Yazdani SK, Virmani R, and Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 55: 1649-1660, 2010.
11. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, and Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776, 2003.
12. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, and Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378: 1847-1857, 2011.
13. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Cha-vakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, and Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324: 1710-1713, 2009.
14. Bry M, Kivela R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, Carmeliet P, Lemstrom KB, Shibuya M, Yla-Herttuala S, Alhonen L, Mervaala E, Andersson LC, Knuuti J, and Ali-talo K. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 122: 1725-1733, 2010.
15. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, and Cao Y. Angiogenic syner-gism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613, 2003.
16. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, and Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fen-estrations, and permeability. Circ Res 94: 664-670, 2004.
17. Capoccia BJ, Gregory AD, and Link DC. Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion. J Leukoc Biol 84: 760-768, 2008.
18. Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, Addis R, Spinetti G, Losa S, Masson R, Baker AH, Agami R, le Sage C, Condorelli G, Madeddu P, Martelli F, and Emanueli C. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothe-lial function and reparative angiogenesis after limb ischemia. Circulation 123: 282-291, 2011.
19. Carmeliet P and Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307, 2011.
20. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, and Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864, 2004.
21. Cho HJ, Lee N, Lee JY, Choi YJ, Ii M, Wecker A, Jeong JO, Curry C, Qin G, and Yoon YS. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 204: 3257-3269, 2007.
22. Cochain C, Rodero MP, Vilar J, Recalde A, Richart AL, Loinard C, Zouggari Y, Guerin C, Duriez M, Combadiere B, Poupel L, Levy BI, Mallat Z, Combadiere C, and Silvestre JS. Regulation of monocyte subset systemic levels by distinct chemokine receptors controls post-ischaemic neo-vascularization. Cardiovasc Res 88: 186-195, 2010.
23. Di Santo S, Yang Z, Wyler von Ballmoos M, Voelzmann J, Diehm N, Baumgartner I, and Kalka C. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 4: e5643, 2009.
24. Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V, Kobayashi H, Shido K, Lyden D, Sato TN, Rabbany SY, and Rafii S. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468: 310-315, 2010.
25. Ding BS, Nolan DJ, Guo P, Babazadeh AO, Cao Z, Ro-senwaks Z, Crystal RG, Simons M, Sato TN, Worgall S, Shido K, Rabbany SY, and Rafii S. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147: 539-553, 2011.
26. Dobrucki LW, Tsutsumi Y, Kalinowski L, Dean J, Gavin M, Sen S, Mendizabal M, Sinusas AJ, and Aikawa R. Analysis of angiogenesis induced by local IGF-1 expression after myocardial infarction using microSPECT-CT imaging. J Mol Cell Cardiol 48: 1071-1079, 2010.
27. Fadini GP, Losordo D, and Dimmeler S. Critical reevalua-tion of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110: 624-637, 2012.
28. Feihl F, Liaudet L, Levy BI, and Waeber B. Hypertension and microvascular remodelling. Cardiovasc Res 78: 274-285, 2008.
29. Ferrara N, Gerber HP, and LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
30. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, Sohn-Lee C, Loyer X, Soutschek J, Brand T, Tuschl T, Heineke J, Martin U, Schulte-Merker S, Ertl G, Engelhardt S, Bauersachs J, and Thum T. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124: 720-730, 2011.
31. Foubert P, Matrone G, Souttou B, Lere-Dean C, Barateau V, Plouet J, Le Ricousse-Roussanne S, Levy BI, Silvestre JS, and Tobelem G. Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy. Circ Res 103: 751-760, 2008.
32. Foubert P, Silvestre JS, Souttou B, Barateau V, Martin C, Ebrahimian TG, Lere-Dean C, Contreres JO, Sulpice E, Levy BI, Plouet J, Tobelem G, and Le Ricousse-Roussanne S. PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells. J Clin Invest 117: 1527-1537, 2007.
33. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, and Bauersachs J. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118: 818-827, 2008.
34. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 8: 1907-1939, 2006.
35. Frangogiannis NG, Smith CW, and Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47, 2002.
36. Frontini MJ, Nong Z, Gros R, Drangova M, O'Neil C, Rahman MN, Akawi O, Yin H, Ellis CG, and Pickering JG. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol 29: 421-427, 2011.
37. Geissmann F, Jung S, and Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82, 2003.
38. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, and Ramakrishnan S. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest 120: 4141-4154, 2010.
39. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, and Hammond HK. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an is-chemic region of the heart. Nat Med 2: 534-539, 1996.
40. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, and Cheresh DA. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456: 809-813, 2008.
41. Grundmann S, Hans FP, Kinniry S, Heinke J, Helbing T, Bluhm F, Sluijter JP, Hoefer I, Pasterkamp G, Bode C, and Moser M. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endo-thelial and vascular smooth muscle cells. Circulation 123: 999-1009, 2011.
42. Haider H, Akbar SA, and Ashraf M. Angiomyogenesis for myocardial repair. Antioxid Redox Signal 11: 1929-1944, 2009.
43. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, and Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 267: H1948-H1954, 1994.
44. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, and Dimmeler S. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109: 1615-1622, 2004.
45. Heil M and Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arter-iogenesis). Circ Res 95: 449-458, 2004.
46. Heil M, Ziegelhoeffer T, Pipp F, Kostin S, Martin S, Clauss M, and Schaper W. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283: H2411-H2419, 2002.
47. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, An-gellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, and Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135-1142, 1999.
48. Hirschi KK, Ingram DA, and Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arter-ioscler Thromb Vasc Biol 28: 1584-1595, 2008.
49. Huang M, Nguyen P, Jia F, Hu S, Gong Y, de Almeida PE, Wang L, Nag D, Kay MA, Giaccia AJ, Robbins RC, and Wu JC. Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angio-genesis after myocardial infarction. Circulation 124: S46-S54, 2011.
50. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, and Park YB. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 24: 288-293, 2004.
51. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, Kojima H, and Iwasaka T. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into is-chemic limbs. Circulation 106: 2019-2025, 2002.
52. Iwasaki H, Kawamoto A, Tjwa M, Horii M, Hayashi S, Oyamada A, Matsumoto T, Suehiro S, Carmeliet P, and Asahara T. PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS One 6: e24872, 2011.
53. Johnson C, Sung HJ, Lessner SM, Fini ME, and Galis ZS. Matrix metalloproteinase-9 is required for adequate an-giogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 94: 262-268, 2004.
54. Jurgensen JS, Rosenberger C, Wiesener MS, Warnecke C, Horstrup JH, Grafe M, Philipp S, Griethe W, Maxwell PH, Frei U, Bachmann S, Willenbrock R, and Eckardt KU. Persistent induction of HIF-1alpha and-2alpha in cardio-myocytes and stromal cells of ischemic myocardium. FASEB J 18: 1415-1417, 2004.
55. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, and Thistlethwaite PA. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 46: 2116-2124, 2005.
56. Kumar AH and Caplice NM. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol 30: 1080-1087, 2010.
57. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Py-towski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, and Alitalo K. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 67: 593-599, 2007.
58. Lahteenvuo JE, Lahteenvuo MT, Kivela A, Rosenlew C, Falkevall A, Klar J, Heikura T, Rissanen TT, Vahakangas E, Korpisalo P, Enholm B, Carmeliet P, Alitalo K, Eriksson U, and Yla-Herttuala S. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogen-esis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 119: 845-856, 2009.
59. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, and Drexler H. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neo-vascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933-1939, 2004.
60. Lassaletta AD, Chu LM, and Sellke FW. Therapeutic neo-vascularization for coronary disease: current state and future prospects. Basic Res Cardiol 106: 897-909, 2011.
61. Latronico MV and Condorelli G. Therapeutic use of mi-croRNAs in myocardial diseases. Curr Heart Fail Rep 8: 193-197, 2011.
62. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, and Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342: 626-633, 2000.
63. Leri A, Kajstura J, and Anversa P. Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. Circ Res 109: 941-961, 2011.
64. Leucker TM, Bienengraeber M, Muravyeva M, Baotic I, Weihrauch D, Brzezinska AK, Warltier DC, Kersten JR, and Pratt PF, Jr. Endothelial- cardiomyocyte crosstalk enhances pharmacological cardioprotection. J Mol Cell Cardiol 51: 803-811, 2011.
65. Li J, Hampton T, Morgan JP, and Simons M. Stretch-induced VEGF expression in the heart. J Clin Invest 100: 18-24, 1997.
66. Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, Jeltsch M, Juan TD, Sievers RE, Chorianopoulos E, Wada H, Vanwildemeersch M, Noel A, Foidart JM, Springer ML, von Degenfeld G, Dewerchin M, Blau HM, Alitalo K, Eriksson U, Carmeliet P, and Moons L. Reevaluation of the role of VEGF-B suggests a restricted role in the revascu-larization of the ischemic myocardium. Arterioscler Thromb Vasc Biol 28: 1614-1620, 2008.
67. Loinard C, Ginouves A, Vilar J, Cochain C, Zouggari Y, Recalde A, Duriez M, Levy BI, Pouyssegur J, Berra E, and Silvestre JS. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 120: 50-59, 2009.
68. Losordo DW and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 109: 2692-2697, 2004.
69. Losordo DW and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 109: 2487-2491, 2004.
70. Lu H, Xu X, Zhang M, Cao R, Brakenhielm E, Li C, Lin H, Yao G, Sun H, Qi L, Tang M, Dai H, Zhang Y, Su R, Bi Y, and Cao Y. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collater-ogenesis and cardiac function in pigs. Proc Natl Acad Sci USA 104: 12140-12145, 2007.
71. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, and Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355: 1199-1209, 2006.
72. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Com-pernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, and Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angio-genesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840, 2002.
73. Lyngbaek S, Schneider M, Hansen JL, and Sheikh SP. Cardiac regeneration by resident stem and progenitor cells in the adult heart. Basic Res Cardiol 102: 101-114, 2007.
74. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marban L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, and Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADU-CEUS): a prospective, randomised phase 1 trial. Lancet 379: 895-904, 2012.
75. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, and Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 29: 1807-1818, 2008.
76. Meloni M, Caporali A, Graiani G, Lagrasta C, Katare R, Van Linthout S, Spillmann F, Campesi I, Madeddu P, Quaini F, and Emanueli C. Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 106: 1275-1284, 2010.
77. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, and Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113: 1287-1294, 2006.
78. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, and Matsuda H. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 105: 2556-2561, 2002.
79. Murakami M and Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 15: 215-220, 2008.
80. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, and Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204: 3037-3047, 2007.
81. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Mat-suoka S, Yamanaka S, and Yamashita JK. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 118: 498-506, 2008.
82. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, and Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120: 408-416, 2009.
83. Oh Y, Wei H, Ma D, Sun X, and Liew R. Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart 98: 443-449, 2012.
84. Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, Shimada K, Ogawa H, Daida H, Hattori K, and Ohsaka A. Granulocyte colony-stimulating factor promotes neo-vascularization by releasing vascular endothelial growth factor from neutrophils. Faseb J 19: 2005-2007, 2005.
85. Onimaru M, Yonemitsu Y, Fujii T, Tanii M, Nakano T, Nakagawa K, Kohno R, Hasegawa M, Nishikawa S, and Sueishi K. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. Am J Physiol Heart Circ Physiol 297: H1685-H1696, 2009.
86. Ono K, Matsumori A, Shioi T, Furukawa Y, and Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95: 2552-2558, 1997.
87. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, and Arany Z. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485: 333-338, 2012.
88. Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladstone SR, Friedman M, Sellke FW, and Simons M. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med 1: 1085-1089, 1995.
89. Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbe-link M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Penicaud L, and Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 109: 656-663, 2004.
90. Potente M, Gerhardt H, and Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 146: 873-887, 2011.
91. Pugh CW and Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684, 2003.
92. Qing G and Simon MC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 19: 60-66, 2009.
93. Rufaihah AJ, Huang NF, Jame S, Lee JC, Nguyen HN, Byers B, De A, Okogbaa J, Rollins M, Reijo-Pera R, Gambhir SS, and Cooke JP. Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler Thromb Vasc Biol 31: e72-e79, 2011.
94. Safi J, Jr., DiPaula AF, Jr., Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, and Capogrossi MC. Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. Mi-crovasc Res 58: 238-249, 1999.
95. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Ham-brecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, and Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210-1221, 2006.
96. Schirmer SH, van Nooijen FC, Piek JJ, and van Royen N. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart 95: 191-197, 2009.
97. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, and Kloner RA. Evaluation of the effects of intramyocardial injection of DNA expressing vascular en-dothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323-1330, 2000.
98. Seeger FH, Tonn T, Krzossok N, Zeiher AM, and Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 28: 766-772, 2007.
99. Shah AM and Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 378: 704-712, 2011.
100. Shimazu T, Otani H, Yoshioka K, Fujita M, Okazaki T, and Iwasaka T. Sepiapterin enhances angiogenesis and functional recovery in mice after myocardial infarction. Am J Physiol Heart Circ Physiol 301: H2061-H2072, 2011.
101. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, and Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118, 2005.
102. Silvestre JS, Mallat Z, Tedgui A, and Levy BI. Post-ischaemic neovascularization and inflammation. Cardiovasc Res 78: 242-249, 2008.
103. Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Cler-gue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, and Levy BI. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93: 114-123, 2003.
104. Skuli N, Majmundar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, Runge A, Liu L, Kim MN, Liang J, Schenkel S, Yodh AG, Keith B, and Simon MC. Endothelial HIF-2al-pha regulates murine pathological angiogenesis and revas-cularization processes. J Clin Invest 122:1427-1443, 2012.
105. Spinetti G, Kraenkel N, Emanueli C, and Madeddu P. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 78: 265-273, 2008.
106. Stockmann C, Doedens A, Weidemann A, Zhang N, Ta-keda N, Greenberg JI, Cheresh DA, and Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456: 814-818, 2008.
107. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872, 2007.
108. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, and Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660, 2008.
109. Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, Dai S, Li C, Chen N, Peng Y, Dawn B, Hunt G, Leri A, Kajstura J, Tiwari S, Shirk G, Anversa P, and Bolli R. In-tracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 121: 293-305, 2010.
110. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, and Gurtner GC. Human en-dothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106: 2781-2786, 2002.
111. Tirziu D, Chorianopoulos E, Moodie KL, Palac RT, Zhuang ZW, Tjwa M, Roncal C, Eriksson U, Fu Q, Elfenbein A, Hall AE, Carmeliet P, Moons L, and Simons M. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest 117: 3188-3197, 2007.
112. Tongers J, Losordo DW, and Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 32: 1197-1206, 2011.
113. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, and Simari RD. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the La-teTIME randomized trial. JAMA 306: 2110-2119, 2011.
114. van der Laan AM, Piek JJ, and van Royen N. Targeting angiogenesis to restore the microcirculation after re-perfused MI. Nat Rev Cardiol 6: 515-523, 2009.
115. van Solingen C, de Boer HC, Bijkerk R, Monge M, van Oeveren-Rietdijk AM, Seghers L, de Vries MR, van der Veer EP, Quax PH, Rabelink TJ, and van Zonneveld AJ. MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1 (+)/Lin (-) progenitor cells in ischaemia. Cardiovasc Res 92: 449-455, 2011.
116. Wang J, Hoshijima M, Lam J, Zhou Z, Jokiel A, Dalton ND, Hultenby K, Ruiz-Lozano P, Ross J, Jr., Tryggvason K, and Chien KR. Cardiomyopathy associated with microcircula-tion dysfunction in laminin alpha4 chain-deficient mice. J Biol Chem 281: 213-220, 2006.
117. Watanabe E, Smith DM, Sun J, Smart FW, Delcarpio JB, Roberts TB, Van Meter CH, Jr., and Claycomb WC. Effect of basic fibroblast growth factor on angiogenesis in the in-farcted porcine heart. Basic Res Cardiol 93: 30-37, 1998.
118. Winegrad S, Henrion D, Rappaport L, and Samuel JL. Vascular endothelial cell-cardiac myocyte crosstalk in achieving a balance between energy supply and energy use. Adv Exp Med Biol 453: 507-514, 1998.
119. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyr-idopoulos I, Magner M, Principe N, Kearney M, Hu JS, and Isner JM. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 153: 381-394, 1998.
120. Yang JJ, Kettritz R, Falk RJ, Jennette JC, and Gaido ML. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol 149: 1617-1626, 1996.
121. Yellon DM and Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
122. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, and Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112: 1618-1627, 2005.
123. Yoon CH, Koyanagi M, Iekushi K, Seeger F, Urbich C, Zeiher AM, and Dimmeler S. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 121: 2001-2011, 2010.
124. You D, Cochain C, Loinard C, Vilar J, Mees B, Duriez M, Levy BI, and Silvestre JS. Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension 51: 1537-1544, 2008.
125. Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, Bieche I, Laurendeau I, Galy-Fauroux I, Fischer AM, and Boisson-Vidal C. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 28: 644-650, 2008.
126. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, Kumar A, Rissanen TT, Wang B, Nagai N, Fons P, Fariss R, Zhang Y, Wa-wrousek E, Tansey G, Raber J, Fong GH, Ding H, Green-berg DA, Becker KG, Herbert JM, Nash A, Yla-Herttuala S, Cao Y, Watts RJ, and Li X. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 106: 6152-6157, 2009.